Can Big Data Match Up To The Big Promise?
Executive Summary
Big data offers great promise for improving drug development and regulation, but a number of challenges need to be addressed, such as integrating datasets from disparate sources, ensuring the information can be used for the intended purpose, and balancing the interests of individual patients with wider societal benefits.
You may also be interested in...
Denmark Leads New EU Task Force Exploring Use Of Big Data In Medicines Assessment
EU drug regulators have created a new task force to establish a roadmap and recommendations on how to use big data in the assessment of medicines.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.